Evidence map›Paper›PMID 32048889›Full record

Trial reportHuman vaccines & immunotherapeutics2020

Immunogenicity and safety of a combined DTPa-IPV/Hib vaccine administered as a three-dose primary vaccination course and a booster dose in healthy children in Russia: a phase III, non-randomized, open-label study.

Victor Romanenko, Irina Osipova, Anna Galustyan, Michael Scherbakov, Nathalie Baudson, Déborah Farhi, Luis Anaya, Sherine O Kuriyakose, Nadia Meyer, Winnie Janssens

Open access · hybridAbstract readClinical Trial, Phase III
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Human vaccines & immunotherapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Observational
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Victor RomanenkoChildren's City Hospital №11 , Ekaterinburg, Russian Federation.
Irina OsipovaOOO "ASKO-MED-PLUS" , Barnaul, Russian Federation.
Anna GalustyanMedical Technologies Ltd , St. Petersburg, Russian Federation.
Michael ScherbakovGSK , Moscow, Russian Federation.ORCID 0000-0002-9189-4729
Nathalie BaudsonGSK , Rixensart, Belgium.
Déborah FarhiGSK , Wavre, Belgium.
Luis AnayaGSK , Wavre, Belgium.
Sherine O KuriyakoseGSK Asia Private Ltd ., Bengaluru, India.
Nadia MeyerGSK , Wavre, Belgium.
Winnie JanssensGSK , Wavre, Belgium.ORCID 0000-0003-1314-3468
GlaxoSmithKline (Belgium) · BEChildren's City Clinical Hospital №11 · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We assessed the immunogenicity and safety of the combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus/

Indexed as

Haemophilus influenzae type bHaemophilus VaccinesAntibodies, BacterialChildDiphtheria-Tetanus-Pertussis VaccineHepatitis B VaccinesHumansImmunization, SecondaryInfantPentetic AcidPoliovirus Vaccine, InactivatedRussiaVaccinationVaccines, CombinedAntibodies, BacterialDiphtheria-Tetanus-Pertussis VaccineHaemophilus VaccinesHepatitis B VaccinesPentetic AcidPoliovirus Vaccine, InactivatedVaccines, Combinedacellular pertussisdiphtheriaDTPa-IPV/Hibimmunogenicitypediatric populationpoliovirus Haemophilus influenzae type breactogenicitysafetytetanus

Identifiers

PMID32048889
PMCPMC7553713
OpenAlexW3005727993

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.